Drug Profile
M 7583
Alternative Names: M7583; TL 895Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator EMD Serono
- Developer Kartos Therapeutics; Merck KGaA; Telios Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Myelofibrosis
- Phase I/II Acute myeloid leukaemia; B-cell lymphoma; COVID 2019 infections
Most Recent Events
- 09 Dec 2023 Updated efficacy and adverse events data from a phase I/II trial in B-cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 15 Jun 2023 Pooled safety and pharmacokinetics data from TL-895-204 and TL-895-207 trials in healthy volunteers presented at the 28th Congress of the European Haematology Association (EHA-2023)
- 08 Jun 2023 Pharmacodynamics data from a preclinical trial in Myelofibrosis presented at the 28th Congress of the European Haematology Association (EHA-2023)